A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)

Dyslipidemia Clinical Trial

Official title:

A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of ERN/LRPT in Patients With Dyslipidemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00961636
• Other study ID #: 0524A-102
• Secondary ID: 2009_634
• Status: Completed
• Phase: Phase 3
• First received: August 17, 2009
• Last updated: January 29, 2015
• Start date: October 2009
• Est. completion date: January 2011

Study information

• Verified date: January 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the efficacy of laropiprant (LRPT) to reduce flushing symptoms beyond 6 months and will measure the impact of withdrawal of laropiprant in patients following 20 weeks of stable maintenance therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1152
• Est. completion date: January 2011
• Est. primary completion date: January 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patient is a male, or a female who is unlikely to conceive, as indicated by meeting at least one of the following conditions: (a) Patient is a male.(b) Patient is a female of reproductive potential and either agrees to remain abstinent (if this form of birth control is accepted by local regulatory agencies and review committees as the sole method of birth control) or use (or have their partner use) 2 acceptable methods of birth control within the projected duration of the study.(c) Patient is a female who is not of reproductive potential and therefore eligible to participate in this study without requiring the use of contraception.

• Lipid-modifying therapy (LMT) is appropriate for the patient

• Patient meets one of the following criteria based on the National Cholesterol Education Program Adult Treatment Panel III guidelines : 1) High risk and is on a statin with LDL-cholesterol (LDL-C) <100 mg/dL or intolerant to statins with LDL-C <120 mg/dL; 2) Multiple risk with LDL-C <130 mg/dL; 3) Low risk with LDL-C <190 mg/dL

• Patient has triglyceride levels <500 mg/dL

Exclusion Criteria:

• Patient is pregnant, breast-feeding, or expecting to conceive

• Patient has a history of cancer within 5 years of screening (except certain skin and cervical cancers)

• Female patient plans to donate eggs during the study

• Male patient plans to donate sperm during the study

• Patient has or has a history of any condition, therapy, or lab abnormality that might confound the study results, interfere with participation for the full duration of the study, or make participation in the study not in the patient's best interest

• Patient has donated or received blood within 8 weeks of screening or plans to donate/receive blood during and 8 weeks after the study

• Patient is experiencing menopausal hot flashes

• Patient has chronic heart failure, uncontrolled cardiac arrhythmias, or poorly controlled hypertension

• Patient has type 1 or 2 diabetes and is poorly-controlled, newly diagnosed, has recently had repeated hypoglycemia, or is taking new or recently adjusted antidiabetic medication

• Patient has uncontrolled metabolic or endocrine disease that influences serum lipids or lipoproteins

• Patient has kidney disease

• Patient had active peptic ulcers within 3 months of screening

• Patient has a history of heart attack, stroke, heart bypass surgery, angina, or angioplasty within 3 months of screening

• Patient is human immunodeficiency virus (HIV) positive

• Patient is taking or has taken niacin >50 mg daily within 6 weeks of screening

• Patient has had a change to type or dose of LMT regimen within 6 weeks of Visit 1

• Patient is taking a statin and a fibrate at screening

• Patient is taking a long acting non-steroidal anti-inflammatory drug (NSAID), such as naproxen or aspirin >100 mg per day at screening

• Patient has arterial bleeding

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dyslipidemia
• Dyslipidemias

Intervention

Drug:
• ER niacin (+) laropiprant (ERN/LRPT)
One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks
• ER niacin (+) laropiprant (ERN/LRPT)
One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.
• Extended-release niacin (ERN)
Two 1g tablets ERN (2g total) once daily for 12 weeks.
• Placebo to ERN/LRPT
One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

References & Publications (1)

Maccubbin DL, Chen F, Anderson JW, Sirah W, McCrary Sisk C, Kher U, Olsson AG, Bays HE, Mitchel YB. Effectiveness and safety of laropiprant on niacin-induced flushing. Am J Cardiol. 2012 Sep 15;110(6):817-22. doi: 10.1016/j.amjcard.2012.05.009. Epub 2012 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number Participants With Days Per Week With Global Flushing Severity Score (GFSS) =4 Partitioned Into 6 Categories During the Postwithdrawal Period	Flushing symptoms were recorded using participant's response to the Global Flushing Severity Score (GFSS), which assessed the overall severity of the flushing experience, using a scale of 0 (no symptom) to 10 (extreme). The number of days/week was derived as: 7*(total number of days with GFSS =4 across Weeks 21-32 divided by the total number of days with nonmissing GFSS across the same period). The number of days/week with a GFSS =4 for each participant was listed in 1 of the following 6 categories: 0, >0 to 0.5, >0.5 to 1, >1 to 2, >2 to 3, and >3 days per week.	Week 21 to Week 32	No
Secondary	Number of Participants With Maximum GFSS =4 During the Post-withdrawal Period	Flushing symptoms were recorded using participant's response to the Global Flushing Severity Score (GFSS), which assesses the overall severity of the flushing experience (including redness, warmth, tingling, or itching) using a scale with response categories of None, Mild, Moderate, Severe, and Extreme. The categories were supplemented with numbers 0 to 10 to allow for greater precision within each category (None=0, Mild=1-3, Moderate=4-6, Severe=7-9, Extreme=10). The daily response was recorded in the morning, and reflected the symptoms experienced during the previous 24 hours.	Week 21 to Week 32	No